BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Sponsor
EuMelaReg gGmbH
Study ID
NCT03944356
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dabrafenib and Trametinib — DRUG
    Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.

Study Details

Adjuvant therapy with dabrafenib plus trametinib in melanoma was approved in 2018 by the EMA (EUropean Medicines Agency). The purpose of this non-interventional study is to assess the usage of adjuvant dabrafenib and trametinib in clinical practice, where the patient population may differ from study population.

Key Dates

Start date
Jul 1, 2019
Status verified
Mar 2025
Primary completion
Dec 31, 2023
Completion
Oct 8, 2024

Study Design

Enrollment
232 participants (actual)

Primary Outcome Measure

Median time on treatment [ Time Frame: Date of first dose up to 12 months ]

Related Studies